U.S. Marine and Shipping Stock News

Carnival Corporation is highlighting its Alaska business as a key long-term growth driver, with a focus on integrated cruise and land experiences. The company is investing in higher-value Alaska packages, including expansion of its Denali lodge facilities. This shift positions Alaska as a central part of Carnival's broader business strategy for future expansion. Carnival (NYSE:CCL) is putting fresh emphasis on Alaska at a time when its stock trades around $26.5, with a mixed return profile...

Trade Desk (NasdaqGM:TTD) has launched a major retail data integration with SEVEN-ELEVEN JAPAN. The partnership allows advertisers in Japan to use retail purchase data from 28 million 7-Eleven App members across digital channels. The integration focuses on scalable, always-on audience targeting that aims to respect consumer privacy requirements. Trade Desk operates a global advertising technology platform that connects advertisers to digital media across formats such as display, video, and...

ASML Holding (NasdaqGS:ASML) reports strong Q2 2026 results and raises its quarterly and full-year 2026 sales and margin guidance. Intel Foundry uses ASML's High NA EUV tools for production chips, marking the first high-volume output on this new lithography standard. Management cites robust AI-related demand and outlines plans for significant capacity expansion to support customers. ASML Holding sits at the center of advanced chip production, supplying lithography systems that are essential...

GRAIL (GRAL) is in focus after multiple law firms filed securities fraud class action lawsuits, following disclosure that its NHS Galleri cancer trial did not meet its primary endpoint and was linked to sharp investor losses. See our latest analysis for GRAIL. After the initial 50% drop following the NHS Galleri trial disclosure, GRAIL's recent momentum has picked up, with a 30 day share price return of 22.17% and a 90 day share price return of 46.86%. The 1 year total shareholder return...

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals in a US$10b all cash transaction. The deal brings atumelnant, an advanced clinical stage drug candidate for congenital adrenal hyperplasia, into Vertex's pipeline. The acquisition marks a move by Vertex into adrenal disease therapeutics, expanding beyond its traditional focus areas. For investors following Vertex Pharmaceuticals, this deal signals a push beyond the company’s established franchises and into...

We wouldn't blame SharkNinja, Inc. ( NYSE:SN ) shareholders if they were a little worried about the fact that CJ Xuning...

We wouldn't blame Arcus Biosciences, Inc. ( NYSE:RCUS ) shareholders if they were a little worried about the fact that...

The proposed US$53b bid by Stripe and Advent International for PayPal has pushed digital payments and broader fintech back into the spotlight, with a 28% offer premium hinting at how highly some buyers value this space. For investors, that kind of interest can reshape expectations across the sector, from transaction platforms to tech driven financial services. This article looks at three fintech stocks from our Fintech Sector Stocks screener that are closely tied to this news and explains how...

Arcos Dorados Holdings has delivered a 66.4% gain over the past five years, yet current valuation work suggests the stock may still trade below its intrinsic value, even after a softer recent patch for the share price. Arcos Dorados Holdings is up 66.4% over five years, which puts the current debate squarely on whether that longer term return already reflects the value in the business. The planned redemption of the 6.125% sustainability linked senior notes can support lower interest costs...

Equity Bancshares, Inc. reported second-quarter 2026 results showing net interest income of US$73.87 million, net income of US$26.44 million, basic EPS of US$1.28, and net charge-offs of US$1.7 million, while completing a buyback of 883,707 shares for US$39.09 million. Together, the earnings strength, controlled credit costs, and completion of a multi-quarter share repurchase program highlight management’s focus on profitability and capital deployment. Next, we’ll examine how this strong...

Construction Partners (ROAD) has been in focus after completing its acquisition of Ellsworth Construction in Oklahoma, widening its footprint in the Tulsa and Oklahoma City markets and adding asphalt manufacturing and construction capacity. See our latest analysis for Construction Partners. Despite the Ellsworth acquisition and an upcoming fiscal Q3 results date on 7 August 2026, Construction Partners’ recent share price performance has softened, with the 30 day share price return down 14.5%...

Kaspi.kz (NasdaqGS:KSPI) has introduced Kasper, a new personal AI assistant announced at a company event in Almaty, aiming to personalize how more than 25 million consumers interact with its Super App services. See our latest analysis for Kaspi.kz. Kaspi.kz’s recent Kasper launch lands after a period of solid momentum, with a 30 day share price return of 10.71% and a year to date share price return of 15.02%. The 1 year total shareholder return stands at 10.76%, pointing to interest that has...

Federal research funding is moving into the political spotlight, and that shift could matter a lot for US defense and aerospace stocks. Proposed rules that tighten control over grants, limit international collaboration, and scrutinize diversity related projects may reorder where money, talent, and research momentum flow. For investors, that creates both potential openings and new areas of risk. This article explains how the news could affect US Domestic Defense and Aerospace Stocks and...

CDW stock has fallen about 23% over the past three years, yet the current market price of US$139.38 still screens as cheap against its intrinsic value estimate from a Discounted Cash Flow (DCF) model and against earnings based multiples. The share price has declined 22.7% over three years, which means anyone looking at CDW today is assessing a stock that has already seen a meaningful reset. For long term holders, the key support for valuation is CDW's ability to convert revenue into steady...

Some Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders may be a little concerned to see that the Chief Legal...

Over the last 7 days, the United States market has remained flat, yet it has experienced a robust 20% increase over the past year with earnings forecasted to grow by 18% annually. In this environment, identifying small-cap stocks that are perceived as undervalued and show insider activity can offer intriguing opportunities for investors seeking potential growth.

In the last week, the United States market has stayed flat, yet it is up 20% over the past year with earnings forecasted to grow by 18% annually. In this environment, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors seeking opportunities in potentially undervalued assets.

Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has experienced a notable rise of 20%, with earnings expected to grow by 18% per annum in the coming years. In this environment of growth potential, stocks that exhibit strong insider ownership can be particularly appealing as they suggest confidence from those closest to the company's operations and future prospects.

The United States market remained flat over the last week, yet it has seen a notable 20% rise over the past year, with earnings expected to grow by 18% annually in the coming years. While penny stocks might seem like an outdated term, they continue to represent a viable investment area for those seeking affordability and growth potential. By focusing on smaller or newer companies with strong financials, investors can uncover opportunities that may offer both stability and upside potential.

The United States market has remained flat over the last week but is up 20% over the past year, with earnings expected to grow by 18% per annum. In this context, identifying dividend stocks that offer stable payouts and potential for growth can be a prudent strategy for investors seeking reliable income amid fluctuating market conditions.

The recent price decline of 15% in NeOnc Technologies Holdings, Inc.'s ( NASDAQ:NTHI ) stock may have disappointed...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

We wouldn't blame Planet Labs PBC ( NYSE:PL ) shareholders if they were a little worried about the fact that Robert...

Vertex acquisition terms and what they mean for Crinetics shareholders Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a cash deal valuing Crinetics at about $10b, or $85 per share. The transaction, announced on July 6, 2026, would make Crinetics a wholly owned subsidiary of Vertex if it closes. The financing would be supported by a mix of cash, debt, and committed bridge funding. See our latest analysis for Crinetics...